Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (55)

2024

  1. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  2. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

    The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389

2023

  1. A meta-analysis and a functional study support the influence of mtDNA variant m.16519C on the risk of rapid progression of knee osteoarthritis

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 7, pp. 974-984

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

2022

  1. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751

2021

  1. Serum Proteomic Profiling in Rheumatoid Arthritis by Antibody Suspension Bead Arrays

    Methods in Molecular Biology (Humana Press Inc.), pp. 143-151

2020

  1. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 5, pp. 1101-1108

  2. Hydrogen sulfide biosynthesis is impaired in the osteoarthritic joint

    International Journal of Biometeorology, Vol. 64, Núm. 6, pp. 997-1010

2019

  1. Analysis of endogenous peptides released from osteoarthritic cartilage unravels novel pathogenic markers

    Molecular and Cellular Proteomics, Vol. 18, Núm. 10, pp. 2018-2028

  2. Anti-inflammatory effects of novel standardized platelet rich plasma releasates on knee osteoarthritic chondrocytes and cartilage in vitro

    Current Pharmaceutical Biotechnology, Vol. 20, Núm. 11, pp. 920-933

2018

  1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)

    Clinical Microbiology and Infection, Vol. 24, pp. S10-S20

  2. What did we learn from 'omics' studies in osteoarthritis

    Current Opinion in Rheumatology, Vol. 30, Núm. 1, pp. 114-120

2017

  1. A multicentric study to evaluate the use of relative retention times in targeted proteomics

    Journal of Proteomics, Vol. 152, pp. 138-149

  2. A replication study and meta-analysis of mitochondrial DNA variants in the radiographic progression of knee osteoarthritis

    Rheumatology (United Kingdom), Vol. 56, Núm. 2, pp. 263-270

  3. Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications

    Expert Review of Proteomics, Vol. 14, Núm. 5, pp. 431-444

  4. Discovery of circulating proteins associated to knee radiographic osteoarthritis

    Scientific Reports, Vol. 7, Núm. 1

  5. MALDI mass spectrometry imaging in rheumatic diseases

    Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1865, Núm. 7, pp. 784-794

  6. Mass spectrometry imaging: A novel technology in rheumatology

    Nature Reviews Rheumatology, Vol. 13, Núm. 1, pp. 52-63

  7. Multiplexed mass spectrometry monitoring of biomarker candidates for osteoarthritis

    Journal of Proteomics, Vol. 152, pp. 216-225

  8. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9